How ‘precise’ has lung cancer treatment become?
Precision oncology is evolving from advanced to early-stage NSCLC, highlights Prof. Enriqueta Felip in her Heine H. Hansen Award lecture at ELCC 2024
A new combination treatment shows early promise in GEP-NECs
Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure
Can sarcomas benefit from targeted treatments active in other tumour types?
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
New hope for MDM2 inhibition in liposarcomas?
An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited
Desmoid tumours: nirogacestat improves quality of life also in stable disease
In a post hoc analysis of the DeFi trial, a reduction in symptom burden was reported, with benefits occurring early in treated patients
Should rare cancers still be (in) a niche of oncology?
ESMO is sustaining its efforts to give rare cancers a more prominent place in oncology
Centralisation of care in rare cancers – what are the next steps?
Innovative models and increased cross-border collaborations can further support the implementation of rare cancer reference centres to expedite diagnosis and improve treatment
Studies provide further evidence to support continued imatinib in two different GIST indications
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST
BRCA mutations are associated with worse treatment outcomes in mCRPC
In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalise treatments in the first-line as a study suggests
A multimodal liquid biopsy analysis shows promise in monitoring response to immunotherapy
A study shows that early kinetics in DNA methylation and fragment quantity in plasma can predict response to pembrolizumab in patients with advanced solid tumours